GPR65 Is A Critical Innate Immune Checkpoint In Tumour Associated Macrophages

Logo
Presented by

Barbara Cipriani, PhD

About this talk

- Introduction to the pH sensing GPCR GPR65 as a genetically validated IO target - Discovery of a potent and selective GPR65 antagonist for “macrophage conditioning” in IO - Assessment of the effects of an orally administered GPR65 antagonist in a PDX model of clear cell renal carcinoma

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (37)
Subscribers (2403)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.